AI-generated from publicly available materials.Evvy has successfully raised $40 million in a Series B funding round aimed at enhancing its AI-driven diagnostic tools for women's health.
The funding round, which exceeded expectations, was spearheaded by Catalio Capital Management, with contributions from Rethink Impact, Muse Capital, Alumni Ventures, and several existing investors. Established in 2021 by Priyanka Jain, Laine Bruzek, and Pita Navarro, Evvy specializes in creating a clinical-grade dataset that focuses on the vaginal microbiome and its implications for women's health.
Utilizing its machine learning platform, EvvyAI, the company analyzes extensive biological data to inform diagnostics and treatment strategies. To date, Evvy has served over 100,000 patients and 3,000 practitioners, offering at-home testing and personalized treatment recommendations. The new funding will primarily facilitate further clinical validation of its diagnostic models and enhance distribution through healthcare professionals and partnerships, particularly in the field of fertility, where precision diagnostics are increasingly sought after.
Evvy's ongoing research collaboration with US Fertility aims to explore the connections between the vaginal microbiome and reproductive health. Jain emphasized the need for improved diagnostics in women’s health, noting that many patients face unexplained symptoms that traditional testing fails to address. This funding marks a significant step toward establishing data-driven, precision care as a standard in women's health.